Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
A 10-day low-dose Dacogen regimen showed a 33% response rate in myelofibrosis patients, with a median response duration of seven months. High prognostic scores, elevated fetal hemoglobin, and reduced ...
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results